

Servier presents pipeline of innovative oncology projects at ESMO International Congress

- A Research focused on hard-to-treat cancers to address high unmet medical need among patients.
- Pipeline consists of 40 R&D projects aimed at developing targeted therapies and immunology to treat solid tumors and hematological cancers.
- Sustained investment in oncology accounting for more than 50% of the Group's R&D budget.

Paris, France, September 8, 2022 – Servier, a global pharmaceutical company, will present its pipeline of oncology R&D projects and new study data in the field of gastrointestinal cancers at the annual meeting of the European Society for Medical Oncology (ESMO), to be held from 9-13 September in Paris. This participation underlines the breadth of Servier's oncology pipeline and its commitment to developing innovative targeted therapies for patients with hard-to-treat cancers.

Claude Bertrand, Executive Vice President Research and Development of the Servier Group, said: "ESMO is a major international congress where we can share and discuss our latest scientific and medical advances in oncology with the scientific community. Five years after making our strategic commitment to the fight against cancer, this conference allows us to highlight the progress made by the Group, our teams, and our partners in developing therapeutic solutions to treat patients with hard-to-treat cancers. As a result of innovative and open research, as well as significant and continuous investment, Servier now has 23 oncology projects in clinical development and 17 research projects."

Bertrand Renaud, Chief Patient Officer at Servier, said: "We would like to thank all patients and patient organizations who contribute to medical progress. Our collaboration with the European organization DiCE (Digestive Cancer Europe) on PROMETCO, a real-world study conducted by Servier in metastatic colorectal cancer which will be presented at ESMO, illustrates our commitment to work ever more closely with patients and to integrate their voice at every stage of the medicine life cycle."

Cancer is the second leading cause of death in the world¹. In 2020, the IARC (*International Agency for Research on Cancer*) estimated that there would be 19.3 million new cases of cancer and 10 million deaths from cancer worldwide. To meet the growing medical needs of patients, Servier has made the fight against cancer one of its top priorities and today allocates more than 50% of its R&D budget to oncology.

In the field of solid tumors, Servier is developing treatments that target gastrointestinal cancers - Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Cholangiocarcinoma (a rare and aggressive bile-duct cancer) - and low-grade glioma (brain tumor). In hematology, the Group is continuing its

¹ GLOBOCAN 2020, IARC



research into certain types of leukemia, such as Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL) and Lymphoma.

Servier's oncology R&D programs focus on two approaches: 1) immuno-oncology, which aims to mobilize the immune system against cancer cells, and 2) targeted therapies, which use precision medicine.

To speed up the research and development of innovative treatments, Servier is pursuing an open innovation strategy with pharmaceutical companies, biotechs, prestigious academic institutions, and start-up incubators. The Group has thus far established nearly forty research partnerships and alliances in the field of oncology.

About Servier

Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient's voice at the heart of its activities.

A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.

More information: www.servier.com

Follow us on social media: [LinkedIn](#), [Facebook](#), [Twitter](#)

Press contact:

Sonia Marques

presse@servier.com

Tel: +33 (0)1 55 72 40 21